252 related articles for article (PubMed ID: 1944100)
1. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) of brain tumors.
Rozental JM
Neurol Clin; 1991 May; 9(2):287-305. PubMed ID: 1944100
[TBL] [Abstract][Full Text] [Related]
2. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma.
Oriuchi N; Tomiyoshi K; Inoue T; Ahmad K; Sarwar M; Tokunaga M; Suzuki H; Watanabe N; Hirano T; Horikoshi S; Shibasaki T; Tamura M; Endo K
J Nucl Med; 1996 Mar; 37(3):457-62. PubMed ID: 8772644
[TBL] [Abstract][Full Text] [Related]
3. Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
Bénard F; Romsa J; Hustinx R
Semin Nucl Med; 2003 Apr; 33(2):148-62. PubMed ID: 12756647
[TBL] [Abstract][Full Text] [Related]
4. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
6. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine.
Derlon JM; Petit-Taboué MC; Chapon F; Beaudouin V; Noël MH; Creveuil C; Courtheoux P; Houtteville JP
Neurosurgery; 1997 Feb; 40(2):276-87; discussion 287-8. PubMed ID: 9007859
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma.
De Witte O; Levivier M; Violon P; Salmon I; Damhaut P; Wikler D; Hildebrand J; Brotchi J; Goldman S
Neurosurgery; 1996 Sep; 39(3):470-6; discussion 476-7. PubMed ID: 8875476
[TBL] [Abstract][Full Text] [Related]
8. Assessment of malignancy of glioma by positron emission tomography with 18F-fluorodeoxyglucose and single photon emission computed tomography with thallium-201 chloride.
Tamura M; Shibasaki T; Zama A; Kurihara H; Horikoshi S; Ono N; Oriuchi N; Hirano T
Neuroradiology; 1998 Apr; 40(4):210-5. PubMed ID: 9592789
[TBL] [Abstract][Full Text] [Related]
9. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome.
Valk PE; Budinger TF; Levin VA; Silver P; Gutin PH; Doyle WK
J Neurosurg; 1988 Dec; 69(6):830-8. PubMed ID: 2848111
[TBL] [Abstract][Full Text] [Related]
10. Relation between tissue nature and (18F) fluorodeoxyglucose kinetics evaluated by dynamic positron emission tomography in human brain tumors.
Yamaguchi T; Sasaki H; Ogawa T; Mineura K; Uemura K; Kanno I; Shishido F; Murakami M; Inugami A; Higano S
Acta Radiol Suppl; 1986; 369():415-8. PubMed ID: 2980513
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of brain tumors using positron emission tomography].
Schober O; Meyer GJ
Radiologe; 1992 Jun; 32(6):282-9. PubMed ID: 1322547
[TBL] [Abstract][Full Text] [Related]
12. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain.
Buchpiguel CA; Alavi JB; Alavi A; Kenyon LC
J Nucl Med; 1995 Jan; 36(1):159-64. PubMed ID: 7799071
[TBL] [Abstract][Full Text] [Related]
13. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy.
Pirotte B; Goldman S; Bidaut LM; Luxen A; Stanus E; Brucher JM; Balériaux D; Brotchi J; Levivier M
Acta Neurochir (Wien); 1995; 134(1-2):79-82. PubMed ID: 7668134
[TBL] [Abstract][Full Text] [Related]
14. Modification of glucose metabolism in brain tumors by using cervical spinal cord stimulation.
Clavo B; Robaina F; Montz R; Domper M; Carames MA; Morera J; Pinar B; Hernandez MA; Santullano V; Carreras JL
J Neurosurg; 2006 Apr; 104(4):537-41. PubMed ID: 16619657
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of PET for the evaluation of brain tumors.
Coleman RE; Hoffman JM; Hanson MW; Sostman HD; Schold SC
J Nucl Med; 1991 Apr; 32(4):616-22. PubMed ID: 2013802
[TBL] [Abstract][Full Text] [Related]
16. PET and SPECT studies in children with hemispheric low-grade gliomas.
Juhász C; Bosnyák E
Childs Nerv Syst; 2016 Oct; 32(10):1823-32. PubMed ID: 27659825
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography in patients with glioma. A predictor of prognosis.
Alavi JB; Alavi A; Chawluk J; Kushner M; Powe J; Hickey W; Reivich M
Cancer; 1988 Sep; 62(6):1074-8. PubMed ID: 3261622
[TBL] [Abstract][Full Text] [Related]
18. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma.
Deshmukh A; Scott JA; Palmer EL; Hochberg FH; Gruber M; Fischman AJ
Clin Nucl Med; 1996 Sep; 21(9):720-5. PubMed ID: 8879874
[TBL] [Abstract][Full Text] [Related]
19. PET and SPECT in low-grade glioma.
Minn H
Eur J Radiol; 2005 Nov; 56(2):171-8. PubMed ID: 16233891
[TBL] [Abstract][Full Text] [Related]
20. Persistent twenty-four hour SPECT thallium-201 defects, plasma thallium-201 concentrations and PET metabolic viability.
Brunken RC; Mody FV; Hawkins RA; Nienaber CA; Phelps ME; Schelbert HR
Herz; 1994 Feb; 19(1):28-41. PubMed ID: 8150412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
